


CORE Diagnostics to expand services to 50 new cities in 2024

22 May 2024 | News

Rs 15-20 crore worth investment lined up by CORE Diagnostics to execute new plans this year



On the verge of completing 12 years of excellence in healthcare services this year, CORE Diagnostics has emerged as the fastest growing clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection.

The company has established a central reference laboratory at Gurugram with satellite laboratories in New Delhi, Bengaluru, Lucknow, Guwahati and Bhubaneswar. CORE Diagnostics is also the largest high-end clinical laboratory in India with an international presence in UAE, Central Asia, various countries in South Asia and parts of Africa.

During an exclusive chat with BioSpectrum, Dinesh Chauhan, Chief Executive Officer, CORE Diagnostics, revealed that during FY 23-24, the company has opened a new lab which is located in Secunderabad, to offer a larger range of thorough diagnostic solutions to a larger customer in Telangana and Andhra Pradesh and other parts of Southern India.

“This 4000 square feet new lab has all the latest tools for Histopathology, Immunohistochemistry, Nephropathology, Flow Cytometry, in addition to essential services including Biochemistry, Immunology, Haematology, Clinical Pathology and Serology”, Chauhan said.

Sharing the plans for FY 24-25, Chauhan said, “We plan to expand our reach within India and internationally. Within the country, we have identified around new 50 cities, where we will tie up with local labs and hospitals, and eventually set up our logistics there. We also plan to expand our genomics services across all specialities, i.e. besides oncology. We hope to

explore areas such as neurology, mother & child care, endocrinology and much more.”

With Rs 15-20 crore worth investment lined up to execute new plans this year, CORE Diagnostics is also venturing out into areas such as women’s health, and predictive diagnosis in reproductive health. “We are strengthening our focus on conditions like cervical cancer, by developing at-home tests for HPV”, added Chauhan.

In addition, the company is planning to emerge as one of the largest diagnostics support and service provider for the clinical research organisations in the country.

“Currently we are generating a business of more than Rs 100 crore, and hope to grow by 30-40 per cent with our new plans and opportunities”, Chauhan concluded.